Latest Report on Collaborative Robot (Cobot) Market worth 6-03-2023, 08:34

Waldencast Announces Participation in Upcoming Consumer 3-03-2023, 05:39

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26